Nanobots Clear Vascular Plaque in First Human Trial: New Path for Cardiovascular Disease Treatment
Technion researchers report that their Nanoclear nanobots successfully cleared partial vascular plaque in three coronary artery disease patients during the first human trial, with no serious adverse effects.
Nanobots Clear Vascular Plaque in First Human Trial
On February 15, 2028, a Technion research team published results in Nature Nanotechnology reporting that their Nanoclear nanobots achieved positive results in the first human trial.
Nanoclear consists of approximately 200nm magnetic nanoparticles surface-modified with antibodies that recognize oxidized LDL in atherosclerotic plaques. After IV injection, the nanobots accumulate at plaque sites under external magnetic field guidance, then activate via near-infrared light to release enzymatic agents that dissolve the plaque's lipid core.
In three coronary artery disease patients, Nanoclear cleared an average of 18% of plaque volume in targeted vessel segments. All three patients experienced only mild fever lasting less than 24 hours.
"18% may sound modest, but for severely stenosed vessels, this means the difference between needing a stent and conservative treatment," said lead researcher Prof. Avi Schroeder.
Nanoclear remains in very early stages. Larger safety and efficacy trials are expected to begin in 2029.
Disclaimer
Content is AI-generated. Do not use it as a basis for real decisions. Do not cite it as factual reporting.